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ABSTRACT
We evaluated prognostic factors of melphalan/fludarabine-based dose-reduced allografts in patients with
multiple myeloma. From 1998 to 2002, 120 patients with multiple myeloma were treated with melphalan/
fludarabine followed by allogeneic stem cell transplantation. The cumulative risk at 1 year for treatment-
related mortality (TRM) was 18% (95% confidence interval [CI], 12%-28%). In a multivariate analysis, relapse
after prior high-dose chemotherapy was the most significant risk factor for TRM (hazard ratio [HR], 2.80; 95%
CI, 1.16-6.74; P  .02), relapse (HR, 4.14; 95% CI, 2.04-8.38; P < .001), event-free survival (HR, 3.11; 95%
CI, 1.77-5.46; P < .001), and overall survival (HR, 2.69; 95% CI, 1.35-5.35; P  .005). In addition, relapse was
also significantly diminished by chronic graft-versus-host disease (GVHD) in a time-dependent Cox model
(HR, 0.37; 95% CI, 0.16-0.87; P  .02). At transplantation, 8% of the patients were in complete remission,
whereas 27% had progressive disease. After allografting, 49% achieved complete remission, and 38% achieved
partial remission. In a subgroup of patients with chemosensitivity at transplantation and no relapse after prior
high-dose chemotherapy who underwent transplantation with peripheral blood stem cells (n  46), the
cumulative risk of TRM at 1 year was only 8% (95% CI, 1%-54%). The 2-year estimated event-free and overall
survival was 60% (95% CI, 42%-78%) and 75% (95% CI, 59%-91%), respectively, for related donors (n  34)
and was 81% (95% CI, 59%-100%) and 92% (95% CI, 76%-100%), respectively, for unrelated donors (n 12).
© 2004 American Society for Blood and Marrow Transplantation
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Dose-Reduced Conditioning and Allografting for Multiple Myeloma
BNTRODUCTION
Allogeneic stem cell transplantation may cure
ultiple myeloma (MM). Despite high treatment-re-
ated mortality (TRM) of 17% to 40% [1-5], lower
elapse rates in comparison to autologous transplan-
ation have been reported. These are probably due to
graft-versus-myeloma effect mediated by immuno-
ompetent donor lymphocytes [6]. After allogeneic
tem cell transplantation, a portion of patients
chieved well-documented molecular remission, re-
ulting in long-term freedom from disease [6,7]. De-
pite the reduced TRM after standard conditioning
ver recent years [6], new strategies are still needed to
ecrease the high treatment-related morbidity and
ortality. Recently, reduced-intensity conditioning or
onmyeloablative regimens followed by allogeneic
tem cell transplantation have been successfully un-
ertaken in a variety of hematologic malignancies,
ncluding myeloma [8-15]. In myeloma patients, the
RM was lower than after standard conditioning, and
his allowed us to investigate this approach success-
ully in unrelated donors [16]. Despite the high efﬁ-
acy with high complete remission (CR) rates even in
reatment-refractory patients, the curative potential
nd optimal timing of this approach still have to be
etermined. We here report a multi-institutional
tudy on factors inﬂuencing the outcome of patients
ith MM after dose-reduced conditioning consisting
f melphalan and ﬂudarabine and allogeneic stem cell
ransplantation. This study mainly focused on the op-
imal timing and effect of graft-versus-host disease
GVHD) on the outcome of this new approach in the
reatment of myeloma patients and the identiﬁcation
f patients who may most beneﬁt from this strategy.
One hundred twenty patients with advanced MM
ere enrolled between July 1998 and December 2002
n 3 international studies investigating dose-reduced
onditioning consisting of melphalan/ﬂudarabine fol-
owed by allogeneic stem cell transplantation in MM.
hirty-eight patients underwent dose-reduced alloge-
eic stem cell transplantation as part of an autologous/
llogeneic tandem approach with melphalan (70-140
g/m2) and ﬂudarabine (150-180 mg/m2) followed by
llogeneic stem cell transplantation from related or
nrelated donors [12,16]. The remaining 82 patients
ere treated with dose-reduced allogeneic transplan-
ation as salvage therapy after a relapse to a previous
utograft (n 58) or after a response to chemotherapy
lone (n  24) [17]. These patients received melpha-
an (140-160 mg/m2) and ﬂudarabine (90-180 mg/m2)
To be included, patients were required to have
ufﬁcient cardiac function (ejection fraction 30%), a
reatinine clearance 30 mL/min, a lung diffusion
apacity of at least 50%, and liver transaminases 3
imes the upper limit of normal. Patient characteristics
re shown in detail in Table 1. The median age of the (
B&MTatients was 52 years (range, 31-65 years). There were
3 male and 47 female patients. Seventy-two donors
ere male, and 48 were female. The median 2-mi-
roglobulin level at diagnosis was 2.9 mL/dL (range,
.0-7.0 mL/dL). Cytogenetic ﬂuorescent in situ hy-
ridization (FISH) analysis was available in 45 patients
nd showed deletion 13 in 15 patients. Because of this
ow number, deletion 13 could not be included in the
ultivariate analysis. Thirty-four patients had re-
eived prior radiation therapy, and the median num-
er of previous chemotherapy cycles was 6 (range,
-24). Ninety-six patients had received at least 1 pre-
ious cycle of high-dose chemotherapy followed by
utologous (n  95) or allogeneic (n  1) stem cell
ransplantation. Twelve patients had received 2 cycles
f previous high-dose chemotherapy. The disease sta-
us before allogeneic transplantation was as follows:
R, n  8; partial remission (PR), n  63; minor
esponse, n  3; no change, n  13; and progressive
isease, n  33. Eighty-ﬁve patients received trans-
lants from related and 35 from unrelated donors.
wo patients received stem cell transplants from
LA-B–mismatched related donors, and 2 patients
eceived transplants from mismatched unrelated do-
ors (HLA-A and HLA-DRB1 and -DQB1, respec-
ively). The median time from diagnosis to transplan-
ation was 23 months (range, 13-105 months). The
ytomegalovirus serostatus was positive in 86 patients
nd negative in 34 patients. The source of stem cells
as peripheral blood in 112 patients and bone marrow
n 8 patients. No manipulation of the graft was per-
ormed. The median follow-up of the surviving pa-
ients was 16 months (range, 3-46 months).
ETHODS
Engraftment was deﬁned as a leukocyte count
1  109/L for 3 consecutive days and a nontrans-
used platelet count 20  109/L. HLA-A and -B
ntigens were typed by serologic methods, and HLA-
RB1 alleles were typed with sequence-speciﬁc oli-
onucleotide probes.
Standard criteria were used for the grading of
cute and chronic GVHD [18,19]. Acute GVHD was
reated with high-dose steroids, and extensive chronic
VHD was treated with cyclosporin A and steroids.
hronic GVHD was evaluated in patients who sur-
ived at least 100 days with sustained engraftment.
himerism analysis was performed with an allele-
peciﬁc multiplex polymerase chain reaction (PCR)
echnique or with FISH in case of sex mismatch.
ntibiotic, antiviral, and antifungal prophylaxis was
erformed according to the center’s policy. Response
o treatment was deﬁned according to the European
roup for Blood and Marrow Transplantation
EBMT)/International Bone Marrow Transplant
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7able 1. Patient Characteristics
Variable Data
o. patients 120
ge, y, median (range) 52 (31-65)
ex
Male 73
Female 47
tage
I 2
II 38
III 80
lasma cell leukemia 2
ence-Jones proteinuria (light chain) 21
gA 18
gG 69
onsecretory 7
gM 5
eletion 13 (FISH positive) 15
eletion 13 (FISH negative) 30
eletion 13 (unknown) 75
2-Microglobulin, mg/dL, median (range) (n  65) 2.9 (1-7)
rior radiotherapy
Yes 34
No 54
Unknown 32
o. prior chemotherapies, median (range) 4 (1-26)
o. prior high-dose (HD) chemotherapies
0 24
1 84 (including 1 prior allograft)
2 12
atients with relapse after HD chemotherapy 58
atients with autograft as part of an autologous allorganic approach 38
atients with relapse to at least 1 chemotherapy (including HD chemotherapy) 65
tatus before allografting
CR 8
PR 63
NC 13
MR 3
PD 33
onor
Related 85
Unrelated 35
Related mismatch 2 (2  HLA-B)
Unrelated mismatch 2 (1  HLA-A, 1  HLA-DRB1, -DQB1)
onor sex
Female 48
Male 72
onor age, y, median (range) 49 (10-68)
BO
Match 57
Mismatch 32
Unknown 31
atient CMV status
Positive 86
Negative 34
tem cell source
Peripheral blood stem cells 112
Bone marrow 8
onditioning
Fludarabine
90 mg/m2 47
125 mg/m2 18
150-180 mg/m2 5500
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Dose-Reduced Conditioning and Allografting for Multiple Myeloma
Begistry criteria [20]. Brieﬂy, CR required a disap-
earance of monoclonal gammopathy in serum and
rine as determined by immunoﬁxation analysis for at
east 6 weeks and 5% plasma cells in a bone marrow
spirate. A PR was deﬁned as a 50% reduction, and
minor response was deﬁned as a 25% reduction of
he paraprotein level. No change was deﬁned as a
25% decrease or an increase of the paraprotein.
elapse was deﬁned as recurrence of the monoclonal
rotein or bone marrow plasmocytosis in case of prior
R. Progression of non-CR patients required at least
25% increase of paraprotein or development of new
one lesions. Written, informed consent was obtained
able 1. Patient Characteristics (Continued)
Variable
Melphalan
70 mg/m2
100 mg/m2
140-160 mg/m2
ATG
none
(Fresenius) 30 mg/kg BW
(Fresenius) 60 mg/kg BW
Horse ATG: 15 mg/kg BW
(SangStat) 6.0 mg/kg BW
edian CD34 cell dose/kg BW
YHD prophylaxis
CsA/MTX
CsA/MMF
CsA alone
None
FK506/MMF
g indicates immunoglobulin; FISH, ﬂuorescent in situ hybridizati
minor response; PD, progressive disease; CMV, cytomegaloviru
MTX, methotrexate; MMF, mycophenolate mofetil; GVHD, gFigure 1. Treatment protocols and
B&MTrom each patient, and the local ethics committee
pproved the studies (Figure 1).
VHD Prophylaxis
GVHD prophylaxis consisted of cyclosporin A
lus short-course methotrexate in 111 patients, cyclo-
porin A plus mycophenolate mofetil in 3 patients,
yclosporin A alone in 3 patients, and tacrolimus plus
ycophenolate mofetil in 1 patient. The dose of cy-
losporine A was adjusted to serum levels. In general,
yclosporine A was tapered between day 60 and day
00 if no signs of GVHD were observed. All patients
Data
5
34
81
62
41
15
1
1
5.0  106 (range, 0.4-23)
111
3
3
1
2
, complete remission; PR, partial response; NC, no change; MR,
, body weight; ATG, antithymocyte globulin; CsA, cyclosporin A;
sus-host disease.on; CR
s; BW
raft-vernumber of patients included.
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7ith an unrelated donor and 23 patients with a related
onor received pretransplantation antithymocyte
lobulin (ATG; rabbit Fresenius, 30-60 mg/kg body
eight, n  56; rabbit SangStat, 6.0 mg/kg body
eight, n  1; and horse, 15 mg/kg body weight,
 1).
tatistics
For the analysis, the data of all 3 studies were
ooled. Survival curves were estimated initially by the
aplan-Meier method for descriptive purposes. The
og-rank test was used for comparison of subgroups; if
he number of subgroups exceeded 2 and the sub-
roups had an ordering, the trend version of the log-
ank test was used. Cox proportional hazards models
ere used for multivariate analyses and to produce
verall (average) hazard ratio (HR) estimates in uni-
ariate comparisons of subgroups. The HR is assumed
o be a valid estimate within the framework of the Cox
odel, even in the presence of competing risks. All
omputations were performed in SPSS version 10/11
SPSS Inc., Chicago, IL). In each instance, the pro-
ortionality assumption of the Cox model was veriﬁed
oth by graphical methods (comparison with the
aplan-Meier curves) and by computing a time-de-
endent Cox model, in which a dummy variable indi-
ating whether an event occurred before or after the
edian time to event for all uncensored observations
as introduced as an interaction term with the main
isk factor. This formally tests whether the HR of that
isk factor is signiﬁcantly different at the ﬁrst and
econd half of the survival curve.
The effect of GVHD in a multivariate setting was
nalyzed in a time-dependent Cox model in which the
isk factor GVHD was a dichotomous variable that
witched from 0 to 1 when the event occurred after
ransplantation. Although the HR associated with
uch a time-dependent covariate can be interpreted
linically, survival curves themselves can not be drawn
n a meaningful way to reﬂect the effect of GVHD.
hronic GVHD analysis was performed in a landmark
etting, ie, by selecting all patients alive at day 100 (as
equired by the deﬁnition of GVHD).
Cumulative incidences themselves for TRM and
elapse (the heights of the survival curves) were esti-
ated in the framework of a competing risk model
fter transfer of the data to NCSS version 2001
NCSS, Kaysville, UT), which has a module for cu-
ulative incidence estimation. The probability of
RM and relapse was estimated in 1 model, where
hey were considered competing risks for each other.
ote that the sum of the cumulative incidence esti-
ates of TRM and relapse thus obtained is equal to
1  the estimated event-free survival probability),
hich is not the case with the Kaplan-Meier estimates. t
02ESULTS
ngraftment and Chimerism
Three patients died of treatment-related causes
efore engraftment; all other patients engrafted. The
edian time until leukocyte (1/nL) and platelet
20/nL) engraftment was 15 days (range, 6-47 days)
nd 16 days (range, 4-65 days), respectively. Leuko-
yte and platelet engraftment was faster after related
han after unrelated transplantation (14 versus 15
ays, P  .009; and 14 versus 20 days, P  .005,
espectively). Faster engraftment of leukocytes and
latelets was also observed after peripheral blood stem
ell (PBSC) as compared with bone marrow transplan-
ation (14 versus 18 days, P  .002; and 15 versus 26
ays, P  .002, respectively). Chimerism data are
vailable in 95 patients, and 98% showed complete
himerism in peripheral blood at day 100, whereas in
% a mixed chimerism was described. T-cell chimer-
sm analysis was performed in 42 patients, and 93%
howed complete and 7% mixed chimerism.
raft-versus-Host Disease
Acute GVHD grade II to IV was noted in 55
46%) patients. Forty-ﬁve (38%) did not experience
ny acute GVHD, whereas 30 (25%) experienced mild
cute GVHD grade I. Severe grade III to IV acute
VHD was observed in 21%: grade III in 21 patients
18%) and grade IV in 4 patients (3%). There was no
ifference in grades II to IV and grades III to IV acute
VHD between related and unrelated donors (51%
ersus 50% and 18% versus 22%, respectively). No
igniﬁcant difference in terms of grades II to IV acute
VHD was observed between PBSC and bone mar-
ow transplantation (49% versus 75%; P  .10).
Chronic GVHD was observed in 47% of the pa-
ients: 25% experienced limited and 22% extensive
hronic GVHD. The incidence of chronic GVHD
as similar among patients receiving PBSC or bone
arrow transplants (49% versus 42%; P  .30), al-
hough the number of patients receiving bone marrow
as too small (n  8) to draw deﬁnite conclusions. It
s interesting to note that the incidence of chronic
VHD was lower among patients who received trans-
lants from unrelated as compared with related do-
ors (29% versus 56%; P  .006); this was probably
ue to the incorporation of ATG in all unrelated
ransplants. Although ATG had no effect on acute
VHD, the incidence of chronic GVHD was signif-
cantly inﬂuenced by the use of ATG (23% versus
3%; P  .006). In a multivariate analysis, patient
reated with ATG had a less than 2 times lower inci-
ence of chronic GVHD compared with those who
id not receive ATG (HR, 0.34; 95% conﬁdence in-
erval [CI], 0.16-0.71; P  .004).
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Dose-Reduced Conditioning and Allografting for Multiple Myeloma
Breatment-Related Mortality
The cumulative risk at 1 year for TRM was 18%
95% CI, 12%-28%). The causes of TRM are listed in
able 2. In a univariate analysis, the TRM was lower
mong patients who had not relapsed with a prior
igh-dose chemotherapy regimen (13% versus 25%;
 .01), patients with chemosensitive disease at
ransplantation (15% versus 23%; P  .05), patients
ith a related donor (15% versus 26%; P  .03),
atients who received PBSCs as the graft source (17%
ersus 37%; P  .02), and patients who underwent
ransplantation within 1 year after diagnosis (3% ver-
us 28%; P  .002). A trend toward a lower TRM was
oted among patients who did not receive prior ra-
iotherapy (14% versus 35%; P  .08) and those with
male donor (16% versus 31%; P .10). No effect on
RM was observed for acute GVHD, CD34 cell
ose, dose of melphalan, age, use of ATG, patient’s
ex, or ABO mismatch. In a multivariate analysis using
he Cox regression model, relapse after prior high-
ose chemotherapy was the only factor that signiﬁ-
antly inﬂuenced TRM, with an HR of 2.80 (95% CI,
.16%-6.74%) and a P value of .02 (Figure 2). In a
ubgroup of patients with chemosensitivity and no
elapse to prior high-dose chemotherapy who under-
ent transplantation with PBSCs (n  46), the cumu-
ative risk of nonrelapse mortality at 1 year was only
% (95% CI, 1%-22%) for related (n  34) and 8%
95% CI, 1%-54%) for unrelated (n  12) donors.
esponse
One hundred eight patients were evaluable for
esponse. At the time of allogeneic transplantation,
able 2. Treatment-Related Mortality
Variable n
verall 24
epsis, pneumonia, other infections 8
ungal infection 5
VHD 5
ardiac failure 3
oxicity (multiorgan failure, alveolar hemorrhage) 3igure 2. Cumulative incidence of relapse and treatment-related mortality
B&MTnly 8 patients (8%) were in CR, whereas 33 (27%)
ad progressive disease. After allogeneic transplanta-
ion, 53 patients achieved a CR (49%), 41 patients a
R (38%), and 4 patients (4%) a minor response
ccording to the EBMT criteria, resulting in an over-
ll response rate of 91%. Five patients (5%) achieved
o change, and 5 patients (5%) had progressive disease
fter allogeneic transplantation.
elapse/Progression
The cumulative incidence of relapse/progression
t 2 years for all patients was 43% (95% CI, 33%-
7%). In the univariate analysis, relapse after prior
igh-dose chemotherapy (66% versus 33%; P .001),
hemorefractory disease at transplantation (55% ver-
us 38%; P  .02), and late transplantation 2 years
fter diagnosis (43% versus 41%; P  .05) were the
ost signiﬁcant factors for a higher relapse rate. Lim-
ted data on deletion 13 were available, but despite the
ow number of included patients, the cumulative inci-
ence of relapse was higher in patients with (n  15)
han without (n  30) deletion 13 (56% versus 14%;
 .03). Because of the low number of patients, this
actor could not be included in the multivariate anal-
sis. The use of ATG was not associated with a higher
ncidence of relapse or progression (P  .60). In a
ultivariate analysis, relapse after a prior high-dose
hemotherapy regimen was the only factor that sig-
iﬁcantly inﬂuenced relapse (HR, 4.14; 95% CI, 2.04-
.38; P  .001; Tables 3 and 4 and Figure 2). For
esults concerning the effect of GVHD on relapse, see
elow.
verall Survival
The estimated 2-year overall survival for all pa-
ients was 59% (95% CI, 29%-89%). In the univariate
nalysis, relapse after prior high-dose chemotherapy
43% versus 73%; P  .001), no chemosensitivity at
he time of transplantation (51% versus 66%; P 
03), bone marrow as the stem cell source (31% versus
2%; P  .003), a matched unrelated donor (38%
ersus 66%; P  .01), the use of ATG (47% versusin patients with (right) or without (left) relapse to a prior autograft.
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7able 3. Univariate Analyses of Overall and Event-Free Survival after Melphalan/Fludarabine
Variable OS (2 y), % (95% CI) P Value EFS (2 y), % (95% CI) P Value
ge
<50 y 65 (50-80) .20 35 (15-55) .60
>50 y 55 (42-68) 39 (25-53)
atient sex
Female 63 (47-79) .50 45 (27-63) .20
Male 57 (44-70) 32 (18-56)
eletion 13 (1 y) (1 y)
Yes (n  15) 37 (6-68) .10 27 (0-60) .70
No (n  30) 73 (58-89) 59 (41-77)
2-Microglobulin*
<2 mg/dL 59 (35-73) .90 39 (14-64) .70
>2 mg/dL 60 (45-75) 47 (30-64)
rior radiotherapy
Yes 49 (31-67) .10 12 (0-30) .02
No 64 (49-79) 47 (30-64)
elapse after prior HD chemotherapy
Yes 43 (27-58) .001 16 (2-30) <.001
No 73 (60-86) 52 (36-68)
tatus at transplantation
CR/PR 66 (53-79) .03 45 (30-60) .005
NC/PD 51 (35-67) 25 (9-41)
ransplantation
Unrelated donor 38 (17-59) .01 35 (15-50) .10
Related donor 66 (56-76) 39 (27-51)
onor sex
Female 48 (33-62) .09 40 (24-56) .30
Male 69 (57-81) 35 (19-51)
onor age
>50 y 63 (48-78) .60 44 (14-64) .70
<50 y 58 (41-75) 35 (18-52)
BO
Matched 60 (46-74) .90 37 (22-52) .80
Mismatched 60 (41-79) 42 (14-70)
ource (T y) (1 y) (1 y)
BM 31 (0-64) .003 33 (0-78) .06
PBSC 72 (63-81) 39 (27-51)
ludarabine
<125 mg/m2 58 (44-72) .50 33 (16-50) .90
>125 mg/m2 60 (46-74) 39 (24-54)
elphalan
>100 mg/m2 62 (50-74) .30 40 (34-54) .40
<100 mg/m2 53 (36-70) 33 (16-50)
D34 cell dose (cells per kg BW)
<5  106 59 (44-74) .70 36 (22-50) .80
>5  106 59 (55-73) 42 (25-59)
tatus after allografting
CR 70 (56-84) .10 29 (12-46) .02
Others 61 (45-77) 50 (34-66)
nterval DX-TX
<1 y 78 (62-94) .004 48 (25-71) .002
>1 y 45 (33-57) 28 (16-40)
<2 y 70 (57-83) .006 48 (32-64) .002
>2 y 42 (26-58) 21 (7-35)
ex mismatch
Yes 60 (45-75) .90 38 (22-54) .90
No 60 (46-74) 38 (22-54)
TC
Yes 47 (31-63) .02 31 (14-58) .20
No 69 (57-83) .02 43 (27-69)
S indicates overall survival; EFS, event-free survival; CI, conﬁdence interval; HD, high-dose; CR, complete remission; PR, partial response;
NC, no change; PD, progressive disease; BM, bone marrow; PBSC, peripheral blood stem cells; BW, body weight; DX, diagnosis; TX,
transplantation.
Also not signiﬁcant with a cutoff of 4 or 6 mg/dL.04
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B9%; P  .02), and transplantation at more than 1
ear (45% versus 78%; P  .004) or 2 years (42%
ersus 70%; P  .006) after diagnosis were the signif-
cant factors for an unfavorable overall survival. No
ffect on overall survival was seen for CD34 cell
ose, 2-microglobulin (used with several cutoffs or as
continuous variable), dose of melphalan, age, or
BO mismatch. In a multivariate analysis, relapse af-
er prior high-dose chemotherapy (HR, 2.69; 95% CI,
able 4. Signiﬁcant Factors in the Univariate Analyses for Cumulative
elphalan/Fludarabine
Variable
Relapse:
Cumulative Incid
(2 y), % (95% C
eletion 13 (1 y)
Yes (n  15) 56 (31-100)
No (n  30) 14 (6-35)
elapse after prior HD chemotherapy
Yes 61 (48-80)
No 33 (20-52)
tatus at transplantation
CR/PR 38 (25-56)
NC/PD 55 (38-78)
ransplantation
Unrelated 27 (14-52)
Related 47 (35-62)
ource (1 y) (1 y)
BM 29 (0-96)
PBSC 22 (15-32)
nterval DX-TX
<1 y 45 (26-77)
>1 y 41 (30-56)
<2 y 41 (28-61)
>2 y 43 (29-62)
R, complete remission; PR, partial response; NC, no change; PD,
DX, diagnosis; TX, transplantation; TRM, transplant-related mFigure 3. Overall survival according to relaps
B&MT.35-5.35; P  .005) was the only factor with a signif-
cant adverse effect on outcome. Because only 8 pa-
ients received bone marrow, the stem cell source was
ot included in the multivariate analysis (Tables 3, 4,
nd 5, and Figure 3). For the subgroup of patients
ith chemosensitivity and no relapse to prior high-
ose chemotherapy who underwent transplantation
ith PBSC (n  46), the 2-year estimated overall
urvival was 75% (95% CI, 59%-91%) for related
ce of Relapse and Treatment-related Mortality with
P Value
Cumulative Incidence
TRM (1 y), % (95% CI) P Value
.03 0 .04
27 (15-48)
<.001 25 (16-41) .01
13 (6-25)
.02 15 (8-27) .05
23 (13-40)
.90 26 (14-48) .03
15 (10-26)
(1 y)
.80 37 (3-71) .02
17 (11-26)
.06 3 (0-20) .002
28 (19-41)
.05 9 (4-20) .001
32 (20-49)
sive disease; BM, bone marrow; PBSC, peripheral blood stem cells;
; CI, conﬁdence interval; HD, high-dose.Inciden
ence
I)
progres
ortalitye with prior high-dose chemotherapy.
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7n 34) and 92% (95% CI, 76%-100%) for unrelated
n  12) donors.
vent-Free Survival
The estimated 2-year event-free survival for all
atients was 39% (95% CI, 29%-49%). In the univar-
ate analysis, relapse after prior high-dose chemother-
py (16% versus 52%; P  .001), no chemosensitivity
t the time of transplantation (25% versus 45%; P 
005), prior radiotherapy (12% versus 47%; P .002),
nd transplantation more than 1 year (28% versus
8%; P  .002) or 2 years (21% versus 48%; P  .02)
fter diagnosis were associated with a signiﬁcantly
ower probability of event-free survival. In a multivar-
ate analysis, relapse after prior high-dose chemother-
py was a signiﬁcant factor (HR, 3.11; 95% CI, 1.77-
.46; P  .001) for an inferior event-free survival
Tables 3 and 4). No effect on event-free survival was
een for CD34 cell dose, dose of melphalan, unre-
ated donor, 2-microglobulin, patient’s sex, use of
TG, age, or ABO mismatch. For a subgroup of
atients with chemosensitivity, no relapse to prior
igh-dose chemotherapy, and PBSC transplants (n 
6), the 2-year estimated event-free survival was 60%
95% CI, 42%-78%) for related (n  34) and 81%
95% CI, 59%-100%) for unrelated (n  12) donors.
n this subgroup, no difference in event-free survival
as seen between the autologous/allogeneic (n  31)
nd the allogeneic-only (n  15) approach (54% ver-
us 61%; P  .60).
For the subgroup of patients who had already
xperienced relapse after prior high-dose chemother-
py (n  57), the 1-year event-free survival was better
mong the patients who received only 1 rather than 2
rior high-dose chemotherapies (50% versus 20%;
 .05). Furthermore, in this group of patients, stem
ell transplantation from a related donor resulted in a
etter event-free survival than transplantation from an
nrelated donor (48% versus 20%; P  .03). Patients
ith chemosensitivity (PR or CR) at the time of trans-
lantation had a trend for better event-free survival
han patients with refractory disease (50% versus
able 5. Multivariate Analysis of Overall and Event-Free Survival,
elapse, and Treatment-Related Mortality (Only Signiﬁcant Factors)
Variable
Relapse after Prior
High-Dose Chemotherapy P Value
S, HR (95% CI) 2.69 (1.35-5.35) .005
FS, HR (95% CI) 3.11 (1.77-5.46) <.001
elapse, HR (95% CI) 4.14 (2.04-8.38) <.001
RM, HR (95% CI) 2.80 (1.16-6.74) .02
S, overall survival; HR, hazard ratio; CI, conﬁdence interval; EFS,
event-free survival; TRM, transplant-related mortality.0%; P  .08).
06ffect of Acute and Chronic GVHD
Acute GVHD was found to have no effect on
elapse, overall survival, or event-free survival. How-
ver, because chronic GVHD was found to be a sig-
iﬁcant factor for survival, relapse, and TRM within
he univariate analysis, we ﬁtted a time-dependent
ox model to patients who were alive at day 100.
lthough no effect after occurrence of chronic
VHD was seen for survival and TRM, chronic
VHD clearly affected the subsequent risk of relapse.
atients who experienced chronic GVHD were more
han 2 times less likely to subsequently experience a
elapse than patients without chronic GVHD (HR,
.37; 95% CI, 0.16-0.87; P  .02; Table 6).
ISCUSSION
This large international multicenter study con-
rmed the feasibility and efﬁcacy of melphalan/ﬂu-
arabine-based dose-reduced conditioning followed
y allogeneic stem cell transplantation as a new treat-
ent modality that enhances treatment options in
atients with MM. Besides identifying factors that
nﬂuence survival after dose-reduced conditioning,
he main purpose was to evaluate the effect of timing
f the allograft. In different nationwide multicenter
tudies, melphalan/ﬂudarabine dose-reduced condi-
ioning has been investigated as a single allogeneic
pproach, as an autologous/allografting tandem ap-
roach, or as salvage therapy after relapse with a prior
utograft. This study shows that melphalan/ﬂudara-
ine dose-reduced allogeneic stem cell transplantation
nduces a high CR rate even in patients with progres-
ive disease. However, the results were signiﬁcantly
oorer among patients who had relapsed after a prior
utograft, because most patients will eventually re-
apse. In this subgroup of patients, factors for a pro-
onged event-free survival were chemosensitivity at
he time of transplantation, having a related donor,
nd having only 1 instead of 2 prior high-dose regi-
ens. This is in accordance with previous reports that
howed a signiﬁcantly better disease-free survival for
hemosensitive patients or for patients without ex-
ended prior chemotherapy, including high-dose che-
otherapy [9,11,13,14]. Less pretreatment and che-
osensitivity before allografting has been also
escribed as a favorable prognostic factor before con-
entional sibling stem cell transplantation [3]. The
able 6. Multivariate Time-Dependent Cox Analysis on Relapse
Including All Patients Alive at Day 100)
Variable Relapse HR (95% CI) P Value
elapse to prior high-dose
chemotherapy 4.87 (2.31-10.23) <.001
hronic GVHD 0.37 (0.16-0.89) .02
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Dose-Reduced Conditioning and Allografting for Multiple Myeloma
Bumulative incidence of TRM after dose-reduced al-
ografting at 1 year was 18%; nevertheless, patients
ho experienced relapse after a prior autograft had a
ore than 2 times higher probability of dying from
reatment-related causes than those who did not re-
apse with an autograft. TRM was also higher after
nrelated as compared with related stem cell trans-
lantation in a univariate analysis, but this was mainly
ecause allogeneic transplantation from unrelated do-
ors was more frequently performed in patients with
ore advanced and less chemosensitive disease. In a
ubgroup of 46 patients with chemosensitive disease
nd no prior relapse to an autograft who underwent
ransplantation with peripheral blood progenitor cells,
he TRM was only 6% after related and 8% after
nrelated transplantation. In addition, TRM was also
nﬂuenced by stem cell source, because the use of
BSCs signiﬁcantly decreased mortality as compared
ith bone marrow. However, because of the low num-
er of patients who received bone marrow transplants,
his factor was not included in the multivariate anal-
sis. The importance of peripheral stem cells as a graft
ource after nonmyeloablative stem cell transplanta-
ion has been recently shown by the Seattle group for
he 2-Gy total body irradiation/ﬂudarabine regimen.
his group reported a survival of 57% for the PBSC
roup and 33% for the patients who received bone
arrow from unrelated donors [21].
The low TRM observed in this study was partially
verwhelmed by a high relapse rate, which, again, was
ore than 4 times higher in patients who relapsed
fter a prior autograft. This high relapse rate, ob-
erved despite the high rate of negative immunoﬁx-
tion, indicates the importance of developing new
trategies to prevent relapse or enhance remission
tatus. The importance of molecular remission after
tandard conditioning and allogeneic transplantation
as been recently described by the EBMT [7]: none of
he patients with negative PCR relapsed, whereas
00% of the patients with clinical CR but positive
CR relapsed during follow-up. Therefore, further
trategies should focus on achieving molecular remis-
ion after allografting, such as incorporating early do-
or lymphocyte infusion to induce a graft-versus-my-
loma effect. Another factor that inﬂuenced the
elapse rate was chronic GVHD. Although no effect
f acute GVHD on relapse was seen, patients with
hronic GVHD had a more than 2 times less proba-
ility of relapse in a time-dependent Cox analysis.
robably because of the short follow-up, this en-
anced risk of relapse in patients without chronic
VHD did not lead to a lower overall survival in the
ox model. The effect of chronic GVHD after dose-
educed allografting in myeloma has been recently
escribed by several authors [9,13,15], who showed
hat patients with chronic GVHD had a signiﬁcantly
onger median event-free survival than those who did c
B&MTot experience chronic GVHD (23.5 versus 5.5
onths; P  .05) [13]. These ﬁndings are further
vidence for a strong graft-versus-myeloma effect,
hich should appear in the context of an unspeciﬁc
llogeneic effect. Whether generation of speciﬁc cy-
otoxic T cells against myeloma-speciﬁc targets or
inor histocompatibility antigens will overcome this
roblem is currently under investigation [22]. Because
TG signiﬁcantly reduces the incidence of chronic
VHD, there is some concern about the use of ATG
ithin the conditioning regimen. However, only in
he univariate analysis for overall survival was a sig-
iﬁcantly worse outcome for patients treated with
TG observed, and this was mainly because all unre-
ated transplantations were performed with ATG,
hereas out of 85 related transplantations, only 23
atients received ATG. Therefore, ATG could not be
ound as a signiﬁcant factor in the multivariate anal-
sis. In a univariate and multivariate analysis of only
he related transplantations, no signiﬁcant effect for
TG was seen for overall survival, progression-free
urvival, TRM, or relapse/progression. However, be-
ause of the low number of patients in this study,
urther investigation of the value of ATG, especially in
he HLA-identical sibling setting, is needed.
In contrast to the results of standard conditioning,
2-microglobulin could not be identiﬁed as a negative
isk factor after dose-reduced melphalan/ﬂudarabine
onditioning, either by using different cutoff levels or
y using the variable as a continuous variable. How-
ver, it has to be taken into account that the 2-
icroglobulin values at the time of transplantation
ere available in only 68 patients. We observed a
rend for a better survival in female patients (P  .08)
ut a trend for worse outcome if the graft was from a
emale donor (48% versus 69%; P  .09). Results
rom FISH analysis for deletion 13 were available in a
mall number of patients, and this deletion resulted in
higher relapse risk. The effect of deletion 13 on
utcome after dose-reduced conditioning should be
urther investigated in a larger number of patients.
In conclusion, melphalan/ﬂudarabine-based dose-
educed conditioning followed by allogeneic stem cell
ransplantation is a promising approach in the treat-
ent of MM. Despite the efﬁcacy in terms of response
ven in chemorefractory patients or in patients who
lready relapsed to a prior autograft, the dose-reduced
llograft has only limited value in this setting regard-
ng long-term progression-free survival; different ap-
roaches such as early donor lymphocyte infusion and
ast cyclosporin A tapering should be tested, and the
esults should be compared with other novel strate-
ies, such as thalidomide and proteasome inhibitors.
he most promising strategy is to perform a dose-
educed allograft with related or unrelated donors at
n earlier stage of the disease in patients who are
hemosensitive and have not relapsed with a prior
707
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7utograft, either as a tandem autologous/allogeneic
pproach [12,14] or as a single allogeneic stem cell
ransplantation in patients who responded well to in-
uction chemotherapy. Because of the low TRM, even
n the unrelated setting, further studies should not
nclude only very high-risk patients.
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